CareDx Launches VANTx AI Platform Leveraging Llama 3 for Transplant Analytics
CareDx launched VANTx, an AI-powered cloud-native platform leveraging its proprietary longitudinal solid-organ transplant datasets and Llama 3 for scalable cohort analyses. The platform ingests de-identified molecular test and clinical data, integrates predictive KOAR, SHORE, ALAMO and MAPLE models, and will offer clinician self-service access in 2026.
1. Platform Launch
CareDx has introduced VANTx, an AI-driven, cloud-native clinical data and analytics platform built on its extensive longitudinal transplant datasets. The launch underscores a two-year, multi-million dollar investment in AI architecture designed to turn complex patient data into actionable research and treatment insights.
2. Data Integration and AI Models
VANTx operates on a live pipeline ingesting real-time de-identified molecular test results and clinical trial information. It runs on a Databricks environment using Llama 3 and integrates validated predictive models — KOAR, SHORE, ALAMO and MAPLE — to support kidney, heart, lung and liver transplant research.
3. Availability and Commercial Plans
The platform is available now to transplant centers via CareDx’s medical affairs team and will transition to self-service, permission-based access for clinicians later in 2026. This rollout aims to broaden adoption and accelerate investigator-initiated studies and clinical trial design support.